<DOC>
	<DOCNO>NCT01744613</DOCNO>
	<brief_summary>Antiplatelet therapy clopidogrel recommend follow peripheral endovascular procedure . The clinical significance inadequate response clopidogrel follow percutaneous coronary intervention recently recognized.This study design investigate platelet responsiveness Clopidogrel follow endovascular therapy peripheral arterial disease use VerifyNow P2Y12 point-of-care test determine optimal P2Y12 reactive unites ( PRU ) cut-off value platelet inhibition influence outcome infrainguinal angioplasty stenting patient receive clopidogrel antiplatelet therapy .</brief_summary>
	<brief_title>High Treatment Platelet Reactivity Following Peripheral Endovascular Procedures</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Patients suffer Rutherford 36 stage peripheral arterial disease schedule undergo femoropopliteal infrapopliteal angioplasty stenting . Patients receive Clopidogrel per o 75 mg daily least 1 month prior 1 year procedure . Acute limb ischemia Coagulation disorder Known allergy clopidogrel Failure comply antiplatelet treatment protocol Aortoiliac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Clopidogrel</keyword>
	<keyword>platelet inhibition</keyword>
	<keyword>antiplatelet therapy</keyword>
	<keyword>peripheral arterial disease</keyword>
	<keyword>endovascular treatment</keyword>
	<keyword>angioplasty</keyword>
	<keyword>stenting</keyword>
</DOC>